Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Nerdwallet Inc (NRDS) Price & Performance

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

NRDS trades at $9.55, down 2.75% today, but maintains strong fundamentals with a P/E of 10.71 and P/S of 0.8, indicating potential undervaluation. The company has shown consistent revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive since 2024. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 beat estimates. Technical indicators show a bullish trend with strong moving average signals, though RSI levels suggest potential overbought conditions.

The outlook for NRDS remains positive with analyst consensus at 66.7% buy ratings and projected 27.9% upside potential. Strong profitability metrics include 93.5% gross margins and 18.16% ROE. Key risks include competitive pressures in financial guidance markets and reliance on organic search traffic. The company's improving cash flow from operations ($132M in 2025) supports continued growth initiatives in personal loans and deposit accounts.